This week, our President and Managing Director, Jennifer Che, attended the Asia Summit for Global Health at the Hong Kong Convention and Exhibition Centre (HKCEC). She was truly impressed by the variety of health-related start-ups, projects, prototypes, and collaborations showcased at the event. The advancements in therapeutics, traditional Chinese medicine, diagnostics, surgical equipment, robotics, and AI solutions highlighted the dynamic biotech landscape of Hong Kong today—a stark contrast to when she first arrived.

Jennifer particularly noted the remarkable initiatives emerging from the InnoHK Centres, which stem from collaborations between local and international universities. Reflecting on the event, she echoed Nancy Ip's sentiment at the HKUST reception: “We can’t do it alone. The most important thing is to collaborate.” This collaborative spirit is vital for driving innovation and improving global health outcomes.

我们的过去活动

Recommended Insights

Breaking News: China passes Fourth Amendment to the Chinese Patent Law

2020年10月19日
After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

2021年4月28日
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 3: The 15-Day Mailing Period is Mostly Going Away

2024年2月28日
A Closer Look at the New Presumed Receipt Date Calculation Background China has finally released the long-awaited Patent Law Implementation Regulations (“Regulations”) and associated "Patent Examination Guidelines" (“Guidelines”, similar to the United States' MPEP) which provide further clarity and details of the new Chinese patent law. Today’s article will focus on changes that impact how […]

Breaking: China Released New Implementation Measures for the New Patent Linkage System

2021年7月14日
On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
Top crossarrow-right